Media headlines about Axsome Therapeutics (NASDAQ:AXSM) have been trending positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.2387939720068 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Axsome Therapeutics, Inc. (AXSM) stock price is -29.94% lower to 200- SMA – The Stocks News (press release) (thestocksnews.com)
- Axsome Therapeutics, Inc. (AXSM) – Watch List Unusual Volume stock – Wall Street Morning (wallstreetmorning.com)
- Axsome Therapeutics, Inc., (NASDAQ: AXSM) – Investor’s Alert (Beta Factor in Focus) – Stock Watch (stocksnewstimes.com)
- Hot Tickers: Axsome Therapeutics, Inc. (AXSM), Lincoln National Corporation (LNC) – Market Movers (financialqz.com)
- ‘Thar’ she blows: CRPS bid harpooned by IDMC; Axsome phase III OA effort still afloat (bioworld.com)
AXSM has been the subject of a number of research reports. Zacks Investment Research lowered shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 22nd. Cantor Fitzgerald set a $13.00 price objective on shares of Axsome Therapeutics and gave the stock a “buy” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Axsome Therapeutics has a consensus rating of “Buy” and a consensus target price of $16.90.
WARNING: “Favorable Press Coverage Somewhat Unlikely to Impact Axsome Therapeutics (AXSM) Share Price” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/13/favorable-press-coverage-somewhat-unlikely-to-impact-axsome-therapeutics-axsm-share-price.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.